Published in J Biol Chem on September 14, 2005
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J (2007) 4.66
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci (2014) 2.37
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Protein homeostasis and aging in neurodegeneration. J Cell Biol (2010) 1.76
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int (2008) 1.76
Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci (2008) 1.75
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes (2012) 1.46
Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr (2011) 1.45
Resveratrol: French paradox revisited. Front Pharmacol (2012) 1.40
Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J Biol Chem (2008) 1.33
ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet (2010) 1.32
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem (2007) 1.25
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24
Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases. Cell Cycle (2011) 1.24
Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol (2010) 1.23
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des (2013) 1.22
Promoting successful cognitive aging: a comprehensive review. J Alzheimers Dis (2010) 1.19
Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci (2008) 1.19
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation (2007) 1.17
Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One (2011) 1.15
Natural products as a source of Alzheimer's drug leads. Nat Prod Rep (2010) 1.13
Botanical phenolics and brain health. Neuromolecular Med (2008) 1.11
Dose-dependency of resveratrol in providing health benefits. Dose Response (2010) 1.11
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem (2011) 1.10
Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res (2013) 1.09
Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Curr Psychiatry Rev (2009) 1.09
Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem (2012) 1.05
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med (2011) 1.05
Neuroprotective potential of phytochemicals. Pharmacogn Rev (2012) 1.05
Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Res Notes (2008) 1.02
Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr (2012) 1.02
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology (2015) 1.01
Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta (2010) 1.01
Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. BMC Res Notes (2008) 0.99
Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med (2011) 0.97
Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med (2008) 0.97
Neuronutrition and Alzheimer's disease. J Alzheimers Dis (2010) 0.97
Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev (2010) 0.96
Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition. Front Aging Neurosci (2014) 0.96
Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr) (2012) 0.96
Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol (2010) 0.96
Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. ACS Chem Neurosci (2012) 0.96
Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim Biophys Acta (2014) 0.96
Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience (2010) 0.95
The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging (Albany NY) (2012) 0.94
Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet (2011) 0.94
Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J Biol Chem (2012) 0.94
Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol (2012) 0.93
Sirtuin1 and autophagy protect cells from fluoride-induced cell stress. Biochim Biophys Acta (2013) 0.93
Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol (2013) 0.93
Protective action of resveratrol in human skin: possible involvement of specific receptor binding sites. PLoS One (2010) 0.92
Resveratrol mitigates rat retinal ischemic injury: the roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. J Ocul Pharmacol Ther (2012) 0.92
Neuroprotective effects of berry fruits on neurodegenerative diseases. Neural Regen Res (2014) 0.92
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front Cell Neurosci (2013) 0.91
Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci (2014) 0.91
SIRT1 regulates dendritic development in hippocampal neurons. PLoS One (2012) 0.90
Resveratrol and the eye: activity and molecular mechanisms. Graefes Arch Clin Exp Ophthalmol (2014) 0.90
Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response (2007) 0.89
Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases. Oxid Med Cell Longev (2015) 0.88
CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. J Exp Med (2008) 0.88
Wine polyphenols: potential agents in neuroprotection. Oxid Med Cell Longev (2012) 0.87
Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system. Surg Neurol Int (2012) 0.86
Medications and diet: protective factors for AD? Alzheimer Dis Assoc Disord (2006) 0.85
Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem (2012) 0.85
β-dicarbonyl enolates: a new class of neuroprotectants. J Neurochem (2010) 0.85
Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Front Aging Neurosci (2014) 0.85
Multiomics in grape berry skin revealed specific induction of the stilbene synthetic pathway by ultraviolet-C irradiation. Plant Physiol (2015) 0.84
The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection. Mol Vis (2013) 0.84
Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol (2010) 0.84
The nuclear inclusion a (NIa) protease of turnip mosaic virus (TuMV) cleaves amyloid-β. PLoS One (2010) 0.84
Mutational analysis of the ability of resveratrol to inhibit amyloid formation by islet amyloid polypeptide: critical evaluation of the importance of aromatic-inhibitor and histidine-inhibitor interactions. Biochemistry (2015) 0.84
Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid Med Cell Longev (2012) 0.84
An Organ System Approach to Explore the Antioxidative, Anti-Inflammatory, and Cytoprotective Actions of Resveratrol. Oxid Med Cell Longev (2015) 0.82
Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr (2014) 0.82
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol (2007) 0.82
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochim Biophys Acta (2015) 0.82
Effects of resveratrol on hydrogen peroxide-induced oxidative stress in embryonic neural stem cells. Neural Regen Res (2013) 0.82
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease. J Cell Mol Med (2016) 0.81
Erratum to: resveratrol and red wine, healthy heart and longevity. Heart Fail Rev (2011) 0.81
Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci (2013) 0.81
Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett (2014) 0.81
Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr Pharm Des (2011) 0.80
Viable mouse gene ablations that robustly alter brain Aβ levels are rare. BMC Neurosci (2010) 0.79
Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease. Acta Pharmacol Sin (2011) 0.79
Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int (2014) 0.79
Specific Conditions for Resveratrol Neuroprotection against Ethanol-Induced Toxicity. J Toxicol (2012) 0.79
18α-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures. Antioxid Redox Signal (2016) 0.79
CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation. PLoS One (2008) 0.79
The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease. PLoS One (2015) 0.78
Are certain lifestyle habits associated with lower Alzheimer's disease risk? J Alzheimers Dis (2010) 0.78
Modulation of protein quality control systems by food phytochemicals. J Clin Biochem Nutr (2013) 0.78
Neural protection by naturopathic compounds-an example of tetramethylpyrazine from retina to brain. J Ocul Biol Dis Infor (2009) 0.78
Caloric restriction: beneficial effects on brain aging and Alzheimer's disease. Mamm Genome (2016) 0.78
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.14
CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature (2013) 2.08
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (2010) 1.96
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax (2010) 1.91
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci (2009) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Concepts for risk-based surveillance in the field of veterinary medicine and veterinary public health: review of current approaches. BMC Health Serv Res (2006) 1.81
The beleaguered consultation. Br J Gen Pract (2006) 1.77
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem (2006) 1.68
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
Should the practice of medicine be a deontological or utilitarian enterprise? J Med Ethics (2011) 1.62
Traditional markers of excessive alcohol use. Addiction (2003) 1.62
Patients and the new contracts. BMJ (2003) 1.59
Gold for the NHS. What exactly is being bought with this gold? BMJ (2002) 1.55
Control and elimination of porcine reproductive and respiratory syndrome virus. Virus Res (2010) 1.52
Semantic distance abnormalities in mild cognitive impairment: their nature and relationship to function. Am J Psychiatry (2012) 1.43
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Religious slaughter. Vet Rec (2003) 1.39
The non-principal phenomenon: a threat to continuity of care and patient enablement? Br J Gen Pract (2004) 1.38
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One (2013) 1.29
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol (2006) 1.24
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24
Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci (2002) 1.24
Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann Neurol (2014) 1.23
AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol (2010) 1.22
Discovering discovery patterns with Predication-based Semantic Indexing. J Biomed Inform (2012) 1.22
Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci (2008) 1.19
The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry (2006) 1.16
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
c-Abl in neurodegenerative disease. J Mol Neurosci (2011) 1.15
Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J Neurosci (2007) 1.14
Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry (2004) 1.12
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem (2011) 1.10
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis (2008) 1.10
Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol (2005) 1.06
Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 1.05
Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology (2010) 1.04
Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis (2008) 1.04
Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis (2011) 1.04
A relationship between environmental degradation and mental health in rural Western Australia. Health Place (2009) 1.03
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem (2005) 1.02
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging (2012) 1.01
QOF. Br J Gen Pract (2007) 1.00
Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis (2010) 0.99
Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. BMC Res Notes (2008) 0.99
Molecular evolution and genetics of the Saitohin gene and tau haplotype in Alzheimer's disease and argyrophilic grain disease. J Neurochem (2004) 0.97
Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med (2011) 0.97
Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem (2003) 0.96
Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem (2004) 0.95
Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev (2007) 0.95
Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. J Biol Chem (2003) 0.94
Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet (2011) 0.94
The map is not the territory. Br J Gen Pract (2002) 0.94
Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 0.92
The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol (2003) 0.91
Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. Neurocase (2010) 0.91
CALHM1 controls the Ca²⁺-dependent MEK, ERK, RSK and MSK signaling cascade in neurons. J Cell Sci (2013) 0.90
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med (2011) 0.90
An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem (2013) 0.90
Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol (2005) 0.90
Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis (2004) 0.89
Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis. Am J Geriatr Psychiatry (2012) 0.89
MAPT isoforms: differential transcriptional profiles related to 3R and 4R splice variants. J Alzheimers Dis (2010) 0.87
The exercise prescription. Br J Gen Pract (2010) 0.87
Tensions in commissioning: services for children's speech, language and communication needs in one English region. J Health Serv Res Policy (2012) 0.87
Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiol Dis (2003) 0.86
Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol (2012) 0.86
Protective effects of polysaccharides from soybean meal against X-ray radiation induced damage in mouse spleen lymphocytes. Int J Mol Sci (2011) 0.85
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci U S A (2014) 0.85
Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer's disease. Mech Ageing Dev (2005) 0.85
Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem (2006) 0.85
Adolescents seeking weight management: who is putting their hand up and what are they looking for? J Paediatr Child Health (2011) 0.84
Methods for measuring tau pathology in transgenic mouse models. J Alzheimers Dis (2013) 0.84
Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol (2011) 0.84
Elevated CSF Tau is associated with psychosis in Alzheimer's disease. Am J Psychiatry (2013) 0.84
Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry (2011) 0.84